We are developing new methods to make gene therapy even safer, to better understand stem cells, and to predict the risks of insertion mutagenesis associated with various gene delivery vectors.
My research group studies cytokines and cytokine receptors and uses this research to develop selective designer proteins for the treatment of inflammatory and genetic diseases.
Dr. Dragon works on the development and optimization of innovative approaches using genetically modified T cells to provide novel treatment options for various diseases in the future.
Engineering antigen-specific Tregs to restore immune tolerance in liver autoimmunity and chronic inflammation — without broadly suppressing immune responses.
My lab bioengineers myeloid immune cells from pluripotent stem cells with enhanced potency. Protocols are optimized for cell therapy and high-throughput modelling of bone marrow diseases.
Use of iPS cell technology to develop immune cells and macrophage-based therapies for regenerative medicine, infection treatment, and immunomodulation.
Turning iPSCs into hematopoietic organoids as off-the-shelf immune cell factories through cryopreservation. Bringing scalable, on-demand immune cells closer to reality.
